Overview

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Everolimus
Sirolimus